Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S V Rajkumar

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
Leukemia|May 30, 2008
The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus StatementM A Hussein, F D Vrionis, R Allison, et al.
Heart (British Cardiac Society)|January 10, 2014
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosisA Dispenzieri, M A Gertz, S K Kumar, et al.
Blood Cancer Journal|May 2, 2015
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for deathR Warsame, S K Kumar, M A Gertz, et al.
Blood Cancer Journal|May 30, 2023
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic ExperienceI Vaxman, S K Kumar, F Buadi, et al.
Leukemia|May 24, 2016
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survivalE Muchtar, A Dispenzieri, S K Kumar, et al.
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Leukemia|January 25, 2008
Genetic aberrations and survival in plasma cell leukemiaR E Tiedemann, N Gonzalez-Paz, R A Kyle, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Bone Marrow Transplantation|April 12, 2016
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapyW I Gonsalves, S V Rajkumar, M A Gertz, et al.
Leukemia|June 17, 2024
Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Leukemia|May 30, 2008
The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus StatementM A Hussein, F D Vrionis, R Allison, et al.
Heart (British Cardiac Society)|January 10, 2014
High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosisA Dispenzieri, M A Gertz, S K Kumar, et al.
Blood Cancer Journal|May 2, 2015
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for deathR Warsame, S K Kumar, M A Gertz, et al.
Blood Cancer Journal|May 30, 2023
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic ExperienceI Vaxman, S K Kumar, F Buadi, et al.
Leukemia|May 24, 2016
Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survivalE Muchtar, A Dispenzieri, S K Kumar, et al.
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Leukemia|January 25, 2008
Genetic aberrations and survival in plasma cell leukemiaR E Tiedemann, N Gonzalez-Paz, R A Kyle, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Bone Marrow Transplantation|April 12, 2016
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapyW I Gonsalves, S V Rajkumar, M A Gertz, et al.
Leukemia|June 17, 2024
Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Pageof 18